Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Touat

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Neuro-Oncology|October 10, 2024
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1Martin J van den Bent, Enrico Franceschi, Mehdi Touat, et al.
Annals of Neurology|November 28, 2024
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort StudyElodie Berthet, Antoine Guillonnet, Caroline Houillier, et al.
Neurology|August 10, 2018
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancerMehdi Touat, Thierry Maisonobe, Samuel Knauss, et al.
Frontiers in Cell and Developmental Biology|October 28, 2021
Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number AlterationsAmira Bouzidi, Karim Labreche, Marine Baron, et al.
Investigational New Drugs|November 3, 2017
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumorsRastislav Bahleda, Marie-Cécile Le Deley, Apexa Bernard, et al.
Critical Care Medicine|January 7, 2022
Brain Biopsy for Neurological Diseases of Unknown Etiology in Critically Ill Patients: Feasibility, Safety, and Diagnostic YieldBertrand Mathon, Malory Favreau, Vincent Degos, et al.
Cancer|March 30, 2025
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network studyAlexandre Bertucci, Ondine Dufour, Romain Appay, et al.
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Acta Neuropathologica|December 8, 2023
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisationLucie Auffret, Yassine Ajlil, Arnault Tauziède-Espariat, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Neuro-Oncology|October 10, 2024
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1Martin J van den Bent, Enrico Franceschi, Mehdi Touat, et al.
Annals of Neurology|November 28, 2024
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort StudyElodie Berthet, Antoine Guillonnet, Caroline Houillier, et al.
Neurology|August 10, 2018
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancerMehdi Touat, Thierry Maisonobe, Samuel Knauss, et al.
Frontiers in Cell and Developmental Biology|October 28, 2021
Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number AlterationsAmira Bouzidi, Karim Labreche, Marine Baron, et al.
Investigational New Drugs|November 3, 2017
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumorsRastislav Bahleda, Marie-Cécile Le Deley, Apexa Bernard, et al.
Critical Care Medicine|January 7, 2022
Brain Biopsy for Neurological Diseases of Unknown Etiology in Critically Ill Patients: Feasibility, Safety, and Diagnostic YieldBertrand Mathon, Malory Favreau, Vincent Degos, et al.
Cancer|March 30, 2025
Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network studyAlexandre Bertucci, Ondine Dufour, Romain Appay, et al.
Frontiers in Immunology|January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cellsMarianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2018
BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, Mehdi Touat, Vivek Subbiah, et al.
Acta Neuropathologica|December 8, 2023
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisationLucie Auffret, Yassine Ajlil, Arnault Tauziède-Espariat, et al.
Pageof 10